Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details the acquisition of Ordinary shares by several executives on July 11, 2011, through the Company's Share Reward Plan. The transactions occurred at a price of 1,375.025 pence per share. Participants included Mr. A P Witty, Mr. S Dingemans, Mr. S M Bicknell, Mr. E J Gray, Mr. D S Redfern, Ms. C Thomas, Mr. P C Thomson, Dr. P J T Vallance, and Mrs. V A Whyte. Acquisitions consisted of both personal contributions and company matching contributions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory notification of director shareholdings under Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of 1,375.025 pence per Ordinary share on July 11, 2011.
- Confirm the specific number of shares acquired by each listed executive under the partnership and matching elements of the Share Reward Plan.
- Review the full Share Reward Plan terms to understand the vesting and matching conditions applied to these transactions.